D&A at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rytm:Depreciationdepletionandamortizationpropertyandequipmentincludingintangibleassets.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s D&A?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported D&A of $252K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s D&A decreased by 34.2% year-over-year, from $383K to $252K.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s D&A has grown at a 3.7% compound annual growth rate (CAGR), from $1.16M to $1.34M.
- What does D&A mean?
- This represents the non-cash allocation of the cost of tangible and intangible assets over their estimated useful lives. It reflects the gradual consumption of capital assets used in the company's research and commercialization operations.